Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
61 hedge funds and large institutions have $137M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
177% more capital invested
Capital invested by funds: $49.5M → $137M (+$87.6M)
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
27% more funds holding
Funds holding: 48 → 61 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$18.2M |
| 2 |
CC
Commodore Capital
New York
|
+$14.7M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.47M |
| 4 |
SC
Samlyn Capital
New York
|
+$7.47M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.52M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$597K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$137K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$129K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$128K |
STSA Hedge Fund Activity: Q1 2021 in Review
61 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2021, worth a combined $137M — up 177% from $49.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new STSA positions and 3 closed out — a net gain of 13 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $18.2M. The largest seller was Morgan Stanley, cutting an estimated $2.52M.
- 61 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2021, up from 48 in Q4 2020.
- Funds reported $137M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2021, up 177% quarter-over-quarter.
- 16 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 3 closed out, a net change of +13 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was NEA Management Company, an estimated $18.2M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Morgan Stanley, an estimated $2.52M sold.
Based on aggregated 13F filings for Q1 2021.